small molecule

CLINDESSE

CLINDAMYCIN PHOSPHATE

Loss of exclusivityDecember 2026latest FDA-listed patent expiry
CompanyPADAGIS US LLC

Drug detail

Brand nameCLINDESSE
Active ingredientCLINDAMYCIN PHOSPHATE
StrengthEQ 2% BASE
Dosage formCREAM
RouteVAGINAL
ModalitySmall molecule
FDA approvalNovember 2004
Marketing statusRX

Listed patents

PatentExpiresType
9789057December 2026product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

CLINDESSE patent cliff — loss of exclusivity December 2026 | CliffBio